EGFR and lung carcinoma: We have however applied our NUFSTMtechnology to produce a water‐soluble, nano‐particulated erlotinib, NUFS‐sErt, which showed a comparable efficacy to its parent compound against EGFR‐mutant lung cancer cell lines.